AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15897164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 11994341 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g strontium ranelate per day
Number of subjects: 353
Study 11994341 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g strontium ranelate per day
Number of subjects: 353
Study 11994341 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g strontium ranelate per day
Number of subjects: 353
Study 11994341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 353
Study 10366258 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcing Kidney and Invigorating Spleen Principle (RKISP) with steroid aerosol
Number of subjects: 0
Study 10366258 — intervention group
Group type: COMPARATOR
Intervention: Steroid aerosol
Number of subjects: 0
Study 15278814 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine patch applied for 15 min (Group A)
Number of subjects: 26
Study 15278814 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine patch applied for 30 min (Group B)
Number of subjects: 26
Study 2958035 — intervention group
Group type: EXPERIMENTAL
Intervention: P-contrast (1 g/cm3)
Number of subjects: 122
Study 2958035 — intervention group
Group type: COMPARATOR
Intervention: Barium (Mixobar Ventrikel 400 mg/ml)
Number of subjects: 122
Study 31022311 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of mitomycin-C (MMC)
Number of subjects: 15
Study 31022311 — intervention group
Group type: COMPARATOR
Intervention: Topical application of saline (placebo)
Number of subjects: 15
Study 30544491 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (TC)
Number of subjects: 60
Study 30544491 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintained unaltered lifestyle)
Number of subjects: 60
Study 27903344 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium ionophore A23187 (AOA group)
Number of subjects: 180
Study 27903344 — intervention group
Group type: COMPARATOR
Intervention: Routine ICSI operation (Control group)
Number of subjects: 180
Study 25424464 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated and replicable physical activity programme with approximately 60 minutes of physical activity during school in the second year, along with nutritional education.
Number of subjects: 321
Study 25424464 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 321
Study 25424464 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated and replicable physical activity programme with nutritional education.
Number of subjects: 321
Study 23029716 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 400 mg orally, three times a day for 4 weeks
Number of subjects: 50
Study 23029716 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 50
Study 23029716 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 50
Study 23029716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 20460237 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (6+/‐2 mg/kg)
Number of subjects: 1099
Study 20460237 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (15+/‐2 mg/kg)
Number of subjects: 1099
Study 20460237 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (24+/‐2 mg/kg)
Number of subjects: 1099
Study 20460237 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D (34+/‐2 mg/kg)
Number of subjects: 1099
Study 18687842 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 20
Study 18687842 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 1:80,000 Adrenalin
Number of subjects: 20
Study 15958399 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice daily)
Number of subjects: 70
Study 15958399 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two tablets daily)
Number of subjects: 70
Study 12101458 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved biofeedback integrated system (Ibis) applied to vision
Number of subjects: 28
Study 12101458 — intervention group
Group type: COMPARATOR
Intervention: Placebo training
Number of subjects: 28
Study 10419812 — intervention group
Group type: EXPERIMENTAL
Intervention: Localization of the AT(1) receptor using immunocytochemistry; expression of prorenin, angiotensinogen, and AT(1) receptor mRNA using RT-PCR.
Number of subjects: 0
Study 10419812 — intervention group
Group type: COMPARATOR
Intervention: Localization and expression of RAS components in the placenta; no control group mentioned.
Number of subjects: 0
Study 7556823 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA)
Number of subjects: 255
Study 7556823 — intervention group
Group type: COMPARATOR
Intervention: Intermittent injections (CIT)
Number of subjects: 255
Study 1763599 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg fentanyl
Number of subjects: 164
Study 1763599 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg alfentanil
Number of subjects: 164
Study 1763599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 1763599 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pain
Number of subjects: 164
Study 7073148 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin prophylaxis (5000 U twice daily)
Number of subjects: 1358
Study 7073148 — intervention group
Group type: COMPARATOR
Intervention: Control group (no heparin treatment)
Number of subjects: 1358
Study 7073148 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin prophylaxis
Number of subjects: 1358
Study 31781682 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sirolimus (0.5 mg on alternate days for 24 weeks) combined with conventional glucocorticoids and immunosuppressants
Number of subjects: 62
Study 31781682 — intervention group
Group type: COMPARATOR
Intervention: Conventional glucocorticoids and immunosuppressants
Number of subjects: 62
Study 28731372 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (14,000 IU/day)
Number of subjects: 53
Study 28731372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 27340985 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone hearing application (Hearing Test™ software)
Number of subjects: 0
Study 27340985 — intervention group
Group type: COMPARATOR
Intervention: Pure‐tone audiogram
Number of subjects: 0
Study 24725785 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates exercise (30-min home-based exercises, 5 times per week for 8 weeks)
Number of subjects: 80
Study 24725785 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Pilates exercise)
Number of subjects: 80
Study 21993073 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic exchange program (educational sessions for physicians)
Number of subjects: 68
Study 21993073 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapeutic exchange program)
Number of subjects: 68
Study 21993073 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention region
Number of subjects: 68
Study 21993073 — intervention group
Group type: COMPARATOR
Intervention: Control region
Number of subjects: 68
Study 21993073 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study 19351628 — intervention group
Group type: EXPERIMENTAL
Intervention: Steerable sheath (Agilis NXT)
Number of subjects: 56
Study 19351628 — intervention group
Group type: COMPARATOR
Intervention: Fixed-curve sheath (Mullins sheath)
Number of subjects: 56
Study 19351628 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56
Study 17113170 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 8 mg once daily for 3-6 weeks, followed by 16 mg once daily for 6 months
Number of subjects: 171
Study 17113170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 15066944 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine, 12.5 to 25 mg PO with 16 oz of water
Number of subjects: 13
Study 15066944 — intervention group
Group type: COMPARATOR
Intervention: Phenylpropanolamine, 12.5 to 25 mg PO
Number of subjects: 13
Study 15066944 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine, 30 mg PO with 16 oz of water
Number of subjects: 13
Study 11238281 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary irradiation (gamma rays)
Number of subjects: 0
Study 10921031 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA (10(-6) mmol/L)
Number of subjects: 18
Study 10921031 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent therapy
Number of subjects: 18
Study 10921031 — intervention group
Group type: COMPARATOR
Intervention: Continuous therapy
Number of subjects: 18
Study 10921031 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA treatment
Number of subjects: 18
Study 8080349 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone therapy
Number of subjects: 61
Study 8080349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 2685709 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (Healon) injection (0.50 to 0.75 ml)
Number of subjects: 0
Study 2685709 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sodium hyaluronate injection)
Number of subjects: 0
Study 2685709 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 1272686 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedative medications
Number of subjects: 36
Study 1272686 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (no specific control mentioned)
Number of subjects: 36
Study 30992031 — intervention group
Group type: EXPERIMENTAL
Intervention: Precise visual feedback condition
Number of subjects: 20
Study 30992031 — intervention group
Group type: EXPERIMENTAL
Intervention: Obscure visual feedback condition
Number of subjects: 20
Study 30992031 — intervention group
Group type: EXPERIMENTAL
Intervention: No visual feedback condition
Number of subjects: 20
Study 27614416 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced bipolar device
Number of subjects: 41
Study 27614416 — intervention group
Group type: COMPARATOR
Intervention: Traditional tie and suture
Number of subjects: 41
Study 27614416 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study 25732157 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous androgen deprivation (CAD)
Number of subjects: 0
Study 23702601 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time cardiopulmonary resuscitation guidance
Number of subjects: 141
Study 21851368 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser group treated with Er:YAG laser irradiation (30 mJ per pulse, 10 pps, 60 s)
Number of subjects: 0
Study 21851368 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐MTAD group treated with laser irradiation plus a mixture of doxycycline, tetracycline isomer and citric acid
Number of subjects: 0
Study 21851368 — intervention group
Group type: COMPARATOR
Intervention: RC‐Prep group treated with EDTA gel or cream (RC‐Prep)
Number of subjects: 0
Study 21851368 — intervention group
Group type: COMPARATOR
Intervention: Control group left untreated
Number of subjects: 0
Study 17619911 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim beginning with cycle 1 (primary prophylaxis)
Number of subjects: 852
Study 17619911 — intervention group
Group type: COMPARATOR
Intervention: Pegfilgrastim subsequent to cycle 1 at clinicians' discretion (usual care)
Number of subjects: 852
Study 16254422 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin plus nitroglycerin and verapamil (Group A)
Number of subjects: 406
Study 16254422 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin plus nitroglycerin (Group B)
Number of subjects: 406
Study 16254422 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone (Group C)
Number of subjects: 406
Study 14586186 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced cognitive-behavioral intervention (9 sessions, 4 months)
Number of subjects: 100
Study 14586186 — intervention group
Group type: COMPARATOR
Intervention: Standard counseling and testing intervention (2 sessions)
Number of subjects: 100
Study 10639039 — intervention group
Group type: EXPERIMENTAL
Intervention: SonoVue 0.03 mL/kg
Number of subjects: 12
Study 10639039 — intervention group
Group type: EXPERIMENTAL
Intervention: SonoVue 0.3 mL/kg
Number of subjects: 12
Study 10639039 — intervention group
Group type: EXPERIMENTAL
Intervention: SonoVue (both dosages)
Number of subjects: 12
Study 9022223 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult eye contact maintained during Periods 1 and 3, averted during Periods 2 and 4
Number of subjects: 2
Study 9022223 — intervention group
Group type: COMPARATOR
Intervention: Control infants received eye contact during all periods
Number of subjects: 2
Study 1587965 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mcg triamcinolone acetonide aerosol
Number of subjects: 9
Study 1587965 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mcg triamcinolone acetonide aerosol
Number of subjects: 9
Study 1587965 — intervention group
Group type: EXPERIMENTAL
Intervention: 1600 mcg triamcinolone acetonide aerosol
Number of subjects: 9
Study 4004963 — intervention group
Group type: EXPERIMENTAL
Intervention: Five health status instruments administered before and after total joint arthroplasty
Number of subjects: 50
Study 4004963 — intervention group
Group type: EXPERIMENTAL
Intervention: Five health status instruments
Number of subjects: 50
Study 30773222 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 40 mg/m2 weekly for up to six doses with 41.4-45 Gy external beam radiation therapy followed by high dose rate brachytherapy
Number of subjects: 40
Study 29382797 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1995057 (nebulised TNFR1 antagonist)
Number of subjects: 37
Study 29382797 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 37
Study 27777220 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ART
Number of subjects: 957
Study 27777220 — intervention group
Group type: COMPARATOR
Intervention: Deferred ART
Number of subjects: 957
Study 25049001 — intervention group
Group type: EXPERIMENTAL
Intervention: Steps per day (incremental increases of 1,000 steps)
Number of subjects: 199
Study 25049001 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher step counts
Number of subjects: 199
Study 21909820 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccine
Number of subjects: 0
Study 19415181 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus 75 mg, administered orally once daily for 5 days every 2 weeks
Number of subjects: 12
Study 19415181 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus 75 mg
Number of subjects: 12
Study 19260512 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 0
Study 16380670 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone (8 mg/day)
Number of subjects: 30
Study 16380670 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 11896522 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming the heel (Experimental)
Number of subjects: 100
Study 11896522 — intervention group
Group type: COMPARATOR
Intervention: No warming (Control)
Number of subjects: 100
Study 10327731 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 60 mg, twice a day for 3 months
Number of subjects: 48
Study 10327731 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 48
Study 8725926 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclinometer technique
Number of subjects: 29
Study 8725926 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-Schober sign
Number of subjects: 29
Study 8725926 — intervention group
Group type: EXPERIMENTAL
Intervention: Extension lumbar range of motion
Number of subjects: 29
Study 8725926 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with gender, age, and body weight
Number of subjects: 29
Study 1760067 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual agent therapy (ampicillin and gentamicin)
Number of subjects: 133
Study 1760067 — intervention group
Group type: COMPARATOR
Intervention: Triple agent therapy (ampicillin, gentamicin, and clindamycin)
Number of subjects: 133
Study 7037502 — intervention group
Group type: EXPERIMENTAL
Intervention: guanabenz
Number of subjects: 188
Study 7037502 — intervention group
Group type: COMPARATOR
Intervention: clonidine
Number of subjects: 188
Study 7037502 — intervention group
Group type: EXPERIMENTAL
Intervention: guanabenz and hydrochlorothiazide
Number of subjects: 188
Study 7037502 — intervention group
Group type: EXPERIMENTAL
Intervention: guanabenz or hydrochlorothiazide
Number of subjects: 188
Study 30782938 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety Planning Intervention (SPI) with telephone follow-up and treatment as usual, n=80
Number of subjects: 120
Study 30782938 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual, n=40
Number of subjects: 120
Study 28422600 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised tooth brushing at school once a day after a meal
Number of subjects: 250
Study 28422600 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 250
Study 26402830 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital image guidance using VERION digital marker
Number of subjects: 60
Study 26402830 — intervention group
Group type: COMPARATOR
Intervention: Manual slitlamp‐assisted preoperative marking using pendulum‐attached marker
Number of subjects: 60
Study 22952203 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 16
Study 21299408 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Repositioning Appliance (MARA)
Number of subjects: 23
Study 19712254 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass surgery
Number of subjects: 0
Study 19712254 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous intervention
Number of subjects: 0
Study 19712254 — intervention group
Group type: COMPARATOR
Intervention: Cardiovascular testing
Number of subjects: 0
Study 19712254 — intervention group
Group type: COMPARATOR
Intervention: Revascularization of coronary artery stenoses
Number of subjects: 0
Study 19712254 — intervention group
Group type: COMPARATOR
Intervention: Myocardial stress test
Number of subjects: 0
Study 19712254 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery intervention prior to transplantation
Number of subjects: 0
Study 16707886 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular triamcinolone acetonide (imTA) 40 mg once a month for 6 months followed by 40 mg once every 1.5 months for 1 year (imTA group)
Number of subjects: 89
Study 16707886 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse therapy (PT) using oral prednisone 80 mg for 3 consecutive days once every 3 months (PT group)
Number of subjects: 89
Study 16707886 — intervention group
Group type: COMPARATOR
Intervention: Oral dexamethasone (Dex) 0.5 mg/day for 6 months (Dex group)
Number of subjects: 89
Study 15301776 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable muscle tone measurement device
Number of subjects: 30
Study 15301776 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 30
Study 11271956 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 23
Study 11271956 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 23
Study 11271956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 9004056 — intervention group
Group type: EXPERIMENTAL
Intervention: DMI plus Li (N = 16)
Number of subjects: 31
Study 9004056 — intervention group
Group type: COMPARATOR
Intervention: DMI plus placebo (N = 15)
Number of subjects: 31
Study 8431363 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitator daily diary card for Quality of Life measurement
Number of subjects: 60
Study 8431363 — intervention group
Group type: COMPARATOR
Intervention: Linear Analogue Self‐Assessment and Nottingham Health Profile
Number of subjects: 60
Study 3312789 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential course of 14 days conventional immunosuppression (Lymphocytoglobulin (ALG), azathioprine, steroids) and cyclosporin and steroids thereafter (group A)
Number of subjects: 100
Study 3312789 — intervention group
Group type: COMPARATOR
Intervention: Conventional immunosuppression for 7 days followed by cyclosporin and steroids (group B)
Number of subjects: 100
Study 3312789 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with serum creatinine of less than 2 mg/dl at the time of conversion to cyclosporin
Number of subjects: 100
Study 3312789 — intervention group
Group type: COMPARATOR
Intervention: Patients with serum creatinine of more than 2 mg/dl at the time of conversion to cyclosporin
Number of subjects: 100
Study 31425480 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib plus cobimetinib
Number of subjects: 809
Study 31425480 — intervention group
Group type: COMPARATOR
Intervention: Vemurafenib (monotherapy)
Number of subjects: 809
Study 31394768 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot water extract of Curcuma longa L. (WEC) 900 mg tablets containing 400 μg bisacurone, 80 μg turmeronol A, and 20 μg turmeronol B
Number of subjects: 90
Study 31394768 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot water extract of Curcuma longa L. (WEC)
Number of subjects: 90
Study 31394768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 28607336 — intervention group
Group type: EXPERIMENTAL
Intervention: King Vision™ video laryngoscopy
Number of subjects: 29
Study 28607336 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscopy
Number of subjects: 29
Study 26799907 — intervention group
Group type: EXPERIMENTAL
Intervention: NO-FEAR Airlines (Computer-aided Self-help Treatment); includes psychoeducation, exposure through 6 scenarios with images and sounds related to flying; self-applied via Internet.
Number of subjects: 0
Study 24621972 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG plus medical therapy
Number of subjects: 1212
Study 24621972 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 1212
Study 21178832 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong
Number of subjects: 123